Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead

Thomas Borody, Monika Fischer, Scott Mitchell, Jordana Campbell

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

At its height, the Clostridium difficile infection epidemic caused approximately 7000 infections and 300 deaths per day in the USA. Fecal microbiota transplantation (FMT) has demonstrated extraordinary clinical resolution, C. difficile infection cure rates of over 90%, and low recurrence. In tandem with the rise of FMT, the gastrointestinal microbiome has emerged as a vital organ armed with a wealth of microbe soldiers more powerful than known antibiotics. FMTs reputation has diffused into many new indications yet these appear to be merely the tip of the iceberg when considering its potential applications. FMT as a therapeutic tool has evolved from the original format of blended donor stool and moved towards a refined product comprising a myriad of microbial components, presented aesthetically as encapsulated lyophilized powder.

Original languageEnglish (US)
Pages (from-to)1379-1391
Number of pages13
JournalExpert Review of Gastroenterology and Hepatology
Volume9
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Gastrointestinal Diseases
Clostridium Infections
Clostridium difficile
Military Personnel
Powders
Tissue Donors
Anti-Bacterial Agents
Recurrence
Infection
Fecal Microbiota Transplantation
Therapeutics

Keywords

  • antibiotic resistance
  • fecal microbiota transplantation
  • FMT
  • FSM
  • full spectrum microbiota
  • microbiome
  • probiotics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Fecal microbiota transplantation in gastrointestinal disease : 2015 update and the road ahead. / Borody, Thomas; Fischer, Monika; Mitchell, Scott; Campbell, Jordana.

In: Expert Review of Gastroenterology and Hepatology, Vol. 9, No. 11, 02.11.2015, p. 1379-1391.

Research output: Contribution to journalArticle

@article{934ee0f440194306bafd8565bc3324e8,
title = "Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead",
abstract = "At its height, the Clostridium difficile infection epidemic caused approximately 7000 infections and 300 deaths per day in the USA. Fecal microbiota transplantation (FMT) has demonstrated extraordinary clinical resolution, C. difficile infection cure rates of over 90{\%}, and low recurrence. In tandem with the rise of FMT, the gastrointestinal microbiome has emerged as a vital organ armed with a wealth of microbe soldiers more powerful than known antibiotics. FMTs reputation has diffused into many new indications yet these appear to be merely the tip of the iceberg when considering its potential applications. FMT as a therapeutic tool has evolved from the original format of blended donor stool and moved towards a refined product comprising a myriad of microbial components, presented aesthetically as encapsulated lyophilized powder.",
keywords = "antibiotic resistance, fecal microbiota transplantation, FMT, FSM, full spectrum microbiota, microbiome, probiotics",
author = "Thomas Borody and Monika Fischer and Scott Mitchell and Jordana Campbell",
year = "2015",
month = "11",
day = "2",
doi = "10.1586/17474124.2015.1086267",
language = "English (US)",
volume = "9",
pages = "1379--1391",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Fecal microbiota transplantation in gastrointestinal disease

T2 - 2015 update and the road ahead

AU - Borody, Thomas

AU - Fischer, Monika

AU - Mitchell, Scott

AU - Campbell, Jordana

PY - 2015/11/2

Y1 - 2015/11/2

N2 - At its height, the Clostridium difficile infection epidemic caused approximately 7000 infections and 300 deaths per day in the USA. Fecal microbiota transplantation (FMT) has demonstrated extraordinary clinical resolution, C. difficile infection cure rates of over 90%, and low recurrence. In tandem with the rise of FMT, the gastrointestinal microbiome has emerged as a vital organ armed with a wealth of microbe soldiers more powerful than known antibiotics. FMTs reputation has diffused into many new indications yet these appear to be merely the tip of the iceberg when considering its potential applications. FMT as a therapeutic tool has evolved from the original format of blended donor stool and moved towards a refined product comprising a myriad of microbial components, presented aesthetically as encapsulated lyophilized powder.

AB - At its height, the Clostridium difficile infection epidemic caused approximately 7000 infections and 300 deaths per day in the USA. Fecal microbiota transplantation (FMT) has demonstrated extraordinary clinical resolution, C. difficile infection cure rates of over 90%, and low recurrence. In tandem with the rise of FMT, the gastrointestinal microbiome has emerged as a vital organ armed with a wealth of microbe soldiers more powerful than known antibiotics. FMTs reputation has diffused into many new indications yet these appear to be merely the tip of the iceberg when considering its potential applications. FMT as a therapeutic tool has evolved from the original format of blended donor stool and moved towards a refined product comprising a myriad of microbial components, presented aesthetically as encapsulated lyophilized powder.

KW - antibiotic resistance

KW - fecal microbiota transplantation

KW - FMT

KW - FSM

KW - full spectrum microbiota

KW - microbiome

KW - probiotics

UR - http://www.scopus.com/inward/record.url?scp=84947125813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947125813&partnerID=8YFLogxK

U2 - 10.1586/17474124.2015.1086267

DO - 10.1586/17474124.2015.1086267

M3 - Article

C2 - 26414076

AN - SCOPUS:84947125813

VL - 9

SP - 1379

EP - 1391

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 11

ER -